DK0804239T3 - Lægemiddel mod stress, svækkelse og ældning samt fremgangsmåde til fremstilling deraf - Google Patents
Lægemiddel mod stress, svækkelse og ældning samt fremgangsmåde til fremstilling derafInfo
- Publication number
- DK0804239T3 DK0804239T3 DK94919023T DK94919023T DK0804239T3 DK 0804239 T3 DK0804239 T3 DK 0804239T3 DK 94919023 T DK94919023 T DK 94919023T DK 94919023 T DK94919023 T DK 94919023T DK 0804239 T3 DK0804239 T3 DK 0804239T3
- Authority
- DK
- Denmark
- Prior art keywords
- stress
- drug
- enterosoluble
- vitamin
- manufacturing
- Prior art date
Links
- 229940079593 drug Drugs 0.000 title abstract 5
- 239000003814 drug Substances 0.000 title abstract 5
- 238000000034 method Methods 0.000 title abstract 3
- 230000032683 aging Effects 0.000 title 1
- 230000035882 stress Effects 0.000 title 1
- 238000004519 manufacturing process Methods 0.000 abstract 2
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 abstract 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 abstract 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract 1
- 229930091371 Fructose Natural products 0.000 abstract 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 abstract 1
- 239000005715 Fructose Substances 0.000 abstract 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 abstract 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 abstract 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 abstract 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 abstract 1
- QKHNQACCGKTTKA-UHFFFAOYSA-N O(C1=CC=CC=C1)CC(=O)OC(C)N Chemical class O(C1=CC=CC=C1)CC(=O)OC(C)N QKHNQACCGKTTKA-UHFFFAOYSA-N 0.000 abstract 1
- 229910019142 PO4 Inorganic materials 0.000 abstract 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 abstract 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 abstract 1
- 229930003451 Vitamin B1 Natural products 0.000 abstract 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 abstract 1
- 150000003869 acetamides Chemical class 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 230000001195 anabolic effect Effects 0.000 abstract 1
- 230000003712 anti-aging effect Effects 0.000 abstract 1
- 230000002180 anti-stress Effects 0.000 abstract 1
- 230000001147 anti-toxic effect Effects 0.000 abstract 1
- 229940009098 aspartate Drugs 0.000 abstract 1
- 239000002775 capsule Substances 0.000 abstract 1
- 150000007942 carboxylates Chemical class 0.000 abstract 1
- 230000001925 catabolic effect Effects 0.000 abstract 1
- 230000000295 complement effect Effects 0.000 abstract 1
- 230000001419 dependent effect Effects 0.000 abstract 1
- 230000003284 homeostatic effect Effects 0.000 abstract 1
- 239000011630 iodine Substances 0.000 abstract 1
- 229910052740 iodine Inorganic materials 0.000 abstract 1
- 229910052744 lithium Inorganic materials 0.000 abstract 1
- 239000011777 magnesium Substances 0.000 abstract 1
- 229910052749 magnesium Inorganic materials 0.000 abstract 1
- 229930182817 methionine Natural products 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- QMEYHMGPFYXWNU-UHFFFAOYSA-N n-(2-aminoethyl)-2-phenoxyacetamide Chemical class NCCNC(=O)COC1=CC=CC=C1 QMEYHMGPFYXWNU-UHFFFAOYSA-N 0.000 abstract 1
- 230000000444 normolipidemic effect Effects 0.000 abstract 1
- 230000001590 oxidative effect Effects 0.000 abstract 1
- 230000001717 pathogenic effect Effects 0.000 abstract 1
- 230000007170 pathology Effects 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 abstract 1
- 239000010452 phosphate Substances 0.000 abstract 1
- 229910052700 potassium Inorganic materials 0.000 abstract 1
- 239000011591 potassium Substances 0.000 abstract 1
- 230000002035 prolonged effect Effects 0.000 abstract 1
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 abstract 1
- 230000002195 synergetic effect Effects 0.000 abstract 1
- 229960003495 thiamine Drugs 0.000 abstract 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 abstract 1
- 230000000304 vasodilatating effect Effects 0.000 abstract 1
- 229940124549 vasodilator Drugs 0.000 abstract 1
- 239000003071 vasodilator agent Substances 0.000 abstract 1
- 235000010374 vitamin B1 Nutrition 0.000 abstract 1
- 239000011691 vitamin B1 Substances 0.000 abstract 1
- 235000019158 vitamin B6 Nutrition 0.000 abstract 1
- 239000011726 vitamin B6 Substances 0.000 abstract 1
- 229940011671 vitamin b6 Drugs 0.000 abstract 1
- 239000011701 zinc Substances 0.000 abstract 1
- 229910052725 zinc Inorganic materials 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Diabetes (AREA)
- Toxicology (AREA)
- Hematology (AREA)
- Addiction (AREA)
- Gastroenterology & Hepatology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Steroid Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Materials For Medical Uses (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| BR9408581A BR9408581A (pt) | 1994-06-02 | 1994-06-02 | Medicamento anti-tens o anti-incapacitação e anti-envelhecimento e processo para a sua produção |
| PCT/RO1994/000003 WO1995033486A1 (en) | 1994-06-02 | 1994-06-02 | Anti-stress, anti-impairment and anti-aging drug and process for manufacturing thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK0804239T3 true DK0804239T3 (da) | 2000-04-03 |
Family
ID=25664670
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK94919023T DK0804239T3 (da) | 1994-06-02 | 1994-06-02 | Lægemiddel mod stress, svækkelse og ældning samt fremgangsmåde til fremstilling deraf |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US6174890B1 (de) |
| EP (1) | EP0804239B1 (de) |
| JP (1) | JP3455544B2 (de) |
| AT (1) | ATE184490T1 (de) |
| AU (1) | AU694125B2 (de) |
| BR (1) | BR9408581A (de) |
| CA (1) | CA2191837C (de) |
| DE (1) | DE69420746T2 (de) |
| DK (1) | DK0804239T3 (de) |
| ES (1) | ES2139077T3 (de) |
| WO (1) | WO1995033486A1 (de) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5703127A (en) * | 1996-01-25 | 1997-12-30 | Pak; Kyoungsik | Composition, dosage unit, and method for treating stomach disorders |
| GB2312621B (en) * | 1996-05-02 | 1998-03-11 | Pharma Nord Uk Limited | Anti-oxidant medicament |
| NZ511708A (en) * | 1998-12-01 | 2003-12-19 | Univ Kentucky Res Found | A method for enhancing protective cellular responses to genotoxic stress in skin |
| US6726939B1 (en) | 2000-03-22 | 2004-04-27 | Kyoungsik Pak | Composition and method for reducing blood pressure, alleviating or eliminating angina pectoris and headaches, and enhancing skin and hair |
| DE10018834A1 (de) * | 2000-04-15 | 2001-10-25 | Lohmann Therapie Syst Lts | Transdermale oder transmucosale Darreichungsformen mit einer nicotinhaltigen Wirkstoffkombination zur Raucherentwöhnung |
| EA005383B1 (ru) * | 2001-12-28 | 2005-02-24 | Федеральное Государственное Унитарное Предприятие "Центр Экстремальной Медицины" | Способ фармакологической коррекции работоспособности человека в экстремальных ситуациях |
| US20040001817A1 (en) * | 2002-05-14 | 2004-01-01 | Giampapa Vincent C. | Anti-aging nutritional supplement |
| AU2003264431A1 (en) * | 2002-09-18 | 2004-04-08 | Ajinomoto Co., Inc. | Composition against stress-related diseases |
| ITRN20030021A1 (it) * | 2003-07-21 | 2005-01-22 | Ascor Chimici Srl | Composizione di materia comprendente particelle contenenti cloruro di colina da somministrare in forma ruminalmente protetta e post-ruminalmente efficace. |
| US20050214388A1 (en) * | 2004-02-18 | 2005-09-29 | Gorham Thomas R | Multivitamin formulations containing controlled-release magnesium |
| KR101292492B1 (ko) | 2004-05-11 | 2013-08-01 | 이모셔널 브레인 비.브이. | 약제학적 제형물 및 여성 성기능 부전의 치료에서 그것의용도 |
| ITMI20041820A1 (it) * | 2004-09-24 | 2004-12-24 | Ascor Chimici Srl | Composizione in micro-pellets a rilascio controllato di sostanze fisiologicamente attive, procedimento di preparazione e relativo impiego nel settore zootecnico. |
| US20060153900A1 (en) * | 2005-01-13 | 2006-07-13 | Pins Joel J | Dietary supplement for treatment of lipid risk factors |
| US20060252831A1 (en) * | 2005-05-06 | 2006-11-09 | Christopher Offen | Method for the treatment of magnesium and potassium deficiencies |
| US20060252830A1 (en) * | 2005-05-06 | 2006-11-09 | Brandon Stephen F | Method for the treatment of magnesium and potassium deficiencies |
| US7901710B2 (en) * | 2005-08-04 | 2011-03-08 | Vertical Pharmaceuticals, Inc. | Nutritional supplement for use under physiologically stressful conditions |
| US8202546B2 (en) | 2005-08-04 | 2012-06-19 | Vertical Pharmaceuticals, Inc. | Nutritional supplement for use under physiologically stressful conditions |
| US7998500B2 (en) * | 2005-08-04 | 2011-08-16 | Vertical Pharmaceuticals, Inc. | Nutritional supplement for women |
| US8263137B2 (en) * | 2005-08-04 | 2012-09-11 | Vertical Pharmaceuticals, Inc. | Nutritional supplement for women |
| EP1790343A1 (de) | 2005-11-11 | 2007-05-30 | Emotional Brain B.V. | Pharmazeutische Zusammensetzungen und deren Verwendung zur Behandlung sexueller Störungen der Frau |
| JPWO2007073006A1 (ja) * | 2005-12-22 | 2009-06-04 | 学校法人慶應義塾 | 細胞保護性を有するアミノ酸の増加誘導剤及び増加方法 |
| RU2330659C1 (ru) * | 2006-10-23 | 2008-08-10 | ФГУ Российский научно-исследовательский нейрохирургический институт им. проф. А.Л. Поленова | Способ лечения диэнцефально-катаболического синдрома |
| EP1925307A1 (de) | 2006-11-03 | 2008-05-28 | Emotional Brain B.V. | Verwendung von 3-alpha-androstanediol zur Behandlung sexueller Dysfunktion |
| JP2008174512A (ja) * | 2007-01-22 | 2008-07-31 | Kracie Seiyaku Kk | 起床時疲労感改善用組成物 |
| JP5788715B2 (ja) * | 2011-05-31 | 2015-10-07 | キリンホールディングス株式会社 | 酸素消費量及びエネルギー消費量の低減剤 |
| JP7021108B2 (ja) | 2016-04-19 | 2022-02-16 | コナリス リサーチ インスティテュート アクチェンゲゼルシャフト | ニコチンアミドの経口薬学的組成物 |
| US11229667B2 (en) | 2018-02-19 | 2022-01-25 | Fp Nutraceuticals, Llc | Magnesium/lithium preparations for neuroprotection and neurotrophic benefits |
| JP2021161045A (ja) * | 2020-03-31 | 2021-10-11 | 株式会社古川リサーチオフィス | 亜鉛化合物配合組成物 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3493659A (en) | 1967-10-23 | 1970-02-03 | Hoffmann La Roche | Compositions and process for the production thereof |
-
1994
- 1994-06-02 ES ES94919023T patent/ES2139077T3/es not_active Expired - Lifetime
- 1994-06-02 DE DE69420746T patent/DE69420746T2/de not_active Expired - Lifetime
- 1994-06-02 BR BR9408581A patent/BR9408581A/pt not_active Application Discontinuation
- 1994-06-02 CA CA002191837A patent/CA2191837C/en not_active Expired - Lifetime
- 1994-06-02 AT AT94919023T patent/ATE184490T1/de active
- 1994-06-02 WO PCT/RO1994/000003 patent/WO1995033486A1/en not_active Ceased
- 1994-06-02 EP EP94919023A patent/EP0804239B1/de not_active Expired - Lifetime
- 1994-06-02 US US08/750,159 patent/US6174890B1/en not_active Expired - Lifetime
- 1994-06-02 JP JP50071396A patent/JP3455544B2/ja not_active Expired - Fee Related
- 1994-06-02 AU AU70104/94A patent/AU694125B2/en not_active Ceased
- 1994-06-02 DK DK94919023T patent/DK0804239T3/da active
Also Published As
| Publication number | Publication date |
|---|---|
| US6174890B1 (en) | 2001-01-16 |
| BR9408581A (pt) | 1997-08-26 |
| CA2191837A1 (en) | 1995-12-14 |
| EP0804239B1 (de) | 1999-09-15 |
| AU694125B2 (en) | 1998-07-16 |
| ES2139077T3 (es) | 2000-02-01 |
| DE69420746D1 (de) | 1999-10-21 |
| WO1995033486A1 (en) | 1995-12-14 |
| DE69420746T2 (de) | 2000-06-29 |
| EP0804239A1 (de) | 1997-11-05 |
| AU7010494A (en) | 1996-01-04 |
| CA2191837C (en) | 2002-10-15 |
| JPH10500137A (ja) | 1998-01-06 |
| ATE184490T1 (de) | 1999-10-15 |
| JP3455544B2 (ja) | 2003-10-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK0804239T3 (da) | Lægemiddel mod stress, svækkelse og ældning samt fremgangsmåde til fremstilling deraf | |
| IT1245761B (it) | Formulazioni farmaceutiche contenenti glicosaminoglicani assorbibili per via orale. | |
| CA2407072A1 (en) | Taste masking coating composition | |
| FI823975A0 (fi) | Farmaceutisk flerenhetssammansaettning | |
| RU94026104A (ru) | Фармацевтическая композиция с регулируемым выделением на основе одной или нескольких фармацевтически приемлемых солей гамма-гидроксимасляной кислоты, способ ее получения | |
| AR018829A1 (es) | Formulaciones farmaceuticas solidas de rapida desintegracion, administrables via oral y procedimiento para prepararlos | |
| DE69423028D1 (de) | Zubereitung mit kontrollierter freisetzung, die ein morphinsalz enthält | |
| IL90435A0 (en) | 4-(quinolin-2-yl-methoxy)phenylacetic acid derivatives,their preparation and pharmaceutical compositions containing them | |
| PT100234A (pt) | Novos esteres de alcoois aminados biciclicos e triciclicos, processo para a sua preparacao | |
| DE69430491D1 (de) | Verfahren zur verkapselung von nsaids | |
| FR2612187B1 (fr) | Derives du thiazole actifs sur le systeme cholinergique, leur procede de preparation et compositions pharmaceutiques en contenant | |
| EE03089B1 (et) | Ibuprofeeni sisaldav kihisev ravimpreparaat ja selle valmistamise meetod | |
| KR960021060A (ko) | 경구 투여용 약제학적 조성물 | |
| IT1270239B (it) | Composizione farmaceutica solida contenente acido (s)-2-(4- isobutilfenil) propionico come principio attivo | |
| US20100087546A1 (en) | Use of dimethyl sulfone (msm) to reduce homocysteine levels | |
| BG103005A (en) | Active substance-containing sedimented silicic acids | |
| IT8347760A0 (it) | Menti per la loro produzione e premodificazioni cristalline,procediparati farmaceutici che le contengono | |
| FR3042411B1 (fr) | Composition comprenant un melange de molecules particulieres et utilisation pour agir sur le metabolisme glucidique et/ou lipidique | |
| DE60028730D1 (de) | Multipartikuläre bisoprolol formulierung | |
| IT8220351A0 (it) | Acidi ossazafosforin-4-tio-alcansolfonici , loro sali neutri, procedimento per la loro preparazione e preparati farmaceutici che licontengono. | |
| NO301767B1 (no) | Salt av clavulansyre | |
| CA2002472A1 (en) | Liquid oral formulation | |
| WO2012085954A1 (en) | Combination comprising d-apartic acid and l-arginine or salts thereof for the improvement of cognitive activities and memory in dementia such as dementia senile and alzheimer's disease | |
| BE888528A (nl) | Isoftaalzuurpycolylamidemonohydraat, werkwijze voor de bereinding daarvan en farmaceutische toepassing, | |
| ATE136783T1 (de) | Arzneimittel mit antineoplastischer wirkung enthaltend als wirkstoff octadecyl-(2-(n- methylpiperidino)-ethyl>-phosphat und verfahren zu dessen herstellung |